Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lexaria Bioscience (LEXX) over the last 13 years, with Q4 2025 value amounting to -$37613.0.

  • Lexaria Bioscience's Change in Accured Expenses rose 9528.32% to -$37613.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $1.2 million, marking a year-over-year increase of 58019.09%. This contributed to the annual value of $396637.0 for FY2025, which is 5200.82% down from last year.
  • According to the latest figures from Q4 2025, Lexaria Bioscience's Change in Accured Expenses is -$37613.0, which was up 9528.32% from $4787.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Change in Accured Expenses ranged from a high of $1.5 million in Q1 2025 and a low of -$797423.0 during Q4 2024
  • Its 5-year average for Change in Accured Expenses is $67116.9, with a median of -$419.5 in 2022.
  • Per our database at Business Quant, Lexaria Bioscience's Change in Accured Expenses tumbled by 1382900.82% in 2023 and then soared by 359169.97% in 2025.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Change in Accured Expenses stood at $88819.0 in 2021, then increased by 1.83% to $90442.0 in 2022, then crashed by 255.87% to -$140973.0 in 2023, then tumbled by 465.66% to -$797423.0 in 2024, then surged by 95.28% to -$37613.0 in 2025.
  • Its last three reported values are -$37613.0 in Q4 2025, $4787.0 for Q3 2025, and -$334819.0 during Q2 2025.